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Summary
29-year-old female presenting with an 8-year history of unexplained hypomagnesaemia, which was severe enough to 
warrant intermittent inpatient admission for intravenous magnesium. Urinary magnesium was inappropriately normal in 
the context of hypomagnesaemia indicating magnesium wasting. Ultrasound imaging demonstrated unilateral renal cysts 
and computed tomography of kidneys, ureters and bladder showed a bicornuate uterus. Referral to genetic services and 
subsequent testing revealed a de novo HNF1B deletion.
Background
This case presentation explores the history and treatment 
of a patient with an HNF1B mutation. This patient 
presented with hypomagnesaemia in her late teens 
– a less usual presentation of this condition; cases are 
more commonly picked up prenatally due to abnormal 
kidney echogenicity or cysts. We provide a review of 
the genetic basis for the constellation of features found 
in association with HNF1B mutations, discuss the steps 
taken to make a diagnosis and provide some guidance on 
oral magnesium replacement therapies and their relative 
merits.
Case presentation
A 29-year-old female presented with an eight-year 
history of hypomagnesaemia. This had been noted at the 
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 • HNF1B loss-of-function mutations are one of the most common monogenic causes of congenital anomalies of the 
kidney and urinary tract.
 • Those with HNF1B mutations may have some of a constellation of features (renal and hepatic cysts, deranged liver 
function tests, maturity onset diabetes of the young type 5 (MODY5), bicornuate uterus, hyperparathyroidism, 
hyperuricaemic gout, but presenting features are highly heterogeneous amongst patients and no genotype/
phenotype correlation exists.
 • HNF1B mutations are inherited in an autosomal dominant pattern but up to 50% of cases are de novo.
 • HNF1B mutations can be part of the Chr17q12 deletion syndrome, a contiguous gene deletion syndrome.
 • Inorganic oral magnesium replacements are generally poorly tolerated with side effects of diarrhoea. Organic 
magnesium compounds, such as magnesium aspartate, are better absorbed oral replacement therapies.
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age of 21 years whilst being treated for mumps-related 
pancreatitis. The hypomagnesaemia caused symptoms 
of headaches and lethargy and replacement with 
magnesium glycerophosphate 4 mg three times daily had 
been instituted. It was suspected that her compliance 
with the medication was poor as the patient still 
required occasional inpatient admission for symptomatic 
hypomagnesaemia and received intravenous magnesium 
infusions.
Investigation
Serum magnesium was 0.51 mmol/L at presentation to 
our department, despite the oral replacement therapy. 
24-h urinary magnesium (3.7 mmol/day, normal range: 
3–5 mmol/day) was noted to be inappropriately normal 
in the context of low serum magnesium (0.46 mmol/L, 
normal range: 0.7–1 mmol/L) with hypocalciuria (24-h 
urinary calcium 0.8 mmol/day, normal range: 2.5–
7.5 mmol/day). Serum parathormone was 4.5 pmol/L. 
Diabetes mellitus was excluded by a normal HbA1c 
(33 mmol/mol, non-diabetic <42 mmol/mol) and 
fasting glucose measurement (5 mmol/L, non-diabetic 
<6.1 mmol/L). Subsequent HbA1c checks have all been 
within normal range. Estimated glomerular filtration rate 
was 83 mL/min. CT scanning of the abdomen to exclude 
renal tract calcification revealed the presence of several 
hyperdense rounded lesions in the left kidney. The right 
kidney was normal. A bicornuate uterus was seen (Fig. 1). 
A subsequent ultrasound (Fig. 2) demonstrated 3 cysts in 
the left kidney (upper pole 3.1 cm, mid kidney 1.7 cm and 
lower pole 1.4 cm). The liver, spleen, pancreas and bladder 
were normal.
Treatment
Initially, the patient was commenced on oral 
magnesium glycerol phosphate 4 mg three times daily. 
However, she remained periodically symptomatic and 
was admitted periodically for IV magnesium. Serum 
magnesium ran in the range of 0.46–0.54 mmol/L 
(normal range 0.7–1 mmol/L). Later, this dose was 
doubled for a trial period, with no resulting increase 
in serum magnesium (0.46 mmol/L). The patient 
was changed to oral magnesium aspartate 10 mmol 
twice daily with an appreciable increase in serum 
magnesium levels (0.57–0.61 mmol/L) and reduction 
of her symptoms.
Outcome and follow-up
Follow-up has been over a period of 9 years. Referral was 
made to a genetic testing service, where the patient was 
tested for an HNF1B mutation. A heterozygous whole 
gene deletion was identified in HNF1B. Subsequent 
array-based comparative genomic hybridization analysis 
demonstrated a 1.5 Mb deletion within chromosome 
17q12 (34,822,460-36,375,192, GRCh37/hg19) (Fig.  3). 
Neither parent shared the deletion indicating that it was 
a de novo event in our patient. More recently, the patient 
has sought advice on conception and has been referred 
for pre-implantation screening to eliminate the risk of 
transmission of the HNF1B mutation.
Discussion
This patient had a heterozygote large deletion on 
chromosome 17q12 encompassing several genes (AATF, 
ACACA, C17ORF78, DDX52, DHRS11, DUSP14, GGNBP2, 
HNF1B, LHX1, MRM1, MYO19, PIGW, SYNRG, TADA2A 
Figure 1
Abdominal CT demonstrating bicornuate uterus. Arrows indicate uterine 
‘horns’.
Figure 2
Renal ultrasound showing a renal cyst (arrow).
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and ZNHIT3). One of the genes in this region HNF1B, 
coding for hepatocyte nuclear factor 1 homeobox beta, 
is made up of nine coding exons. HNF1B mutations 
(alongside paired box 2 gene PBX2) are the most common 
monogenic cause of congenital anomalies of the kidney 
and urinary tract (CAKUT) (1), and it is found in 15–23% 
of CAKUT patients (2, 3, 4). Targeted knockdown of Hnf1b 
in mice results in liver cysts (5) and renal cysts (6). HNF1B 
is known to regulate transcription of polycystic kidney 
and hepatic disease (PKHD1), uromodulin (UMOD) and 
polycystic kidney disease 2 (PKD2) (7). Mutations of these 
genes are known to result in renal cystic diseases (7). 
LHX1, coding for LIM homeobox 1, is also found in the 
17q12 area and heterozygote variants are known to cause 
Müllerian duct abnormalities/Mayer-Rokitansky-Küster-
Hauser syndrome (8).
A typical facial phenotype is observed in some patients 
with 17q12 deletions – high rounded forehead, arched 
eyebrows, small chin/set back lower jaw and downward 
slanting eyes. In retrospect, our patient has the latter 
two characteristics. Less commonly, they may be of short 
stature with height in the lower 3% of population and have 
spinal curvature (9). Our patient was shorter than average 
(152 cm) but was not in the bottom 3rd centile for height 
and she had exceeded mid-parental height prediction 
(father 159.5 cm, mother 150 cm, predicted height 148 cm).
Hypomagnesaemia
The occurrence of hypomagnesaemia is described with 
various types of HNF1B mutations (7, 10, 11). It is believed 
to occur through magnesium wasting in the renal distal 
convoluted tubule. The co-existence of hypermagnesuria 
and hypo/normocalciuria helps to localise its site of the 
dysfunction (7). Magnesium is predominately reabsorbed 
in the thick ascending limb of the loop of Henle and 
the distal convoluted tubule. Magnesium and calcium 
reabsorption in the thick ascending limb both rely on 
the adequate function of the intercellular tight junction 
proteins claudin 16 and 19. Failure of these prevents 
paracellular passage of both calcium and magnesium 
and results in the syndrome of familial hypercalciuric 
hypomagnesemia with nephrocalcinosis (12). As 
hypercalciuria is not accompanying hypomagnesaemia in 
Figure 3 
(A) Chromosomal location of the lost chromosomal material on 17q12 (34,822,460-36,375,192; GRCh37/hg19). (B) This region is involved in recurrent 
deletion mutations as it is flanked on each side by highly repetitive segments of genomic material called segmental duplications (A and B blue arrow 
and C and D orange arrow). Since these segmental duplications have a high degree of homology to one another, they can misalign during meiosis 
(middle picture) and give rise to deletions of the intervening genomic interval via non-allelic homologous recombination (marked with staggered lines 
on the middle picture), resulting in the loss of the same unique genomic region (region B and C on the right picture) in different individuals causing the 
17q12 recurrent deletion syndrome (26). Figure was drawn based on illustration in Chen et al. (27).
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HNF1B mutation patients, the site of abnormal magnesium 
handling is unlikely to be in the thick ascending limb .
In the distal convoluted tubule, HNF1B binds to the 
promoter of the FXYD domain containing ion transport 
regulator 2 (FXYD2) gene (7), which encodes the γ-subunit 
of a basal membrane Na+/K+-ATPase in the kidney. This 
γ-subunit helps to stabilise the α-subunit within the Na+/
K+-ATPase. Loss of the γ-subunits affect the Na+-, K+- and 
ATP-binding affinities of the Na+/K+-ATPase (13). Although 
the exact method of extrusion of magnesium from the 
cells of the distal convoluted tubule into the circulation is 
not yet known, one possibility is that reduced activity in 
this Na+/K+-ATPase pump and a consequent reduction in 
Na+ removal from the cell, results in a higher intracellular 
Na+ concentration. This could then prevent its exchange 
for intracellular Mg2+ through the soluble carrier family 
41 member A1 (SLC41A1) (14) or A3 (SLC41A3) (15, 16). 
Mechanisms believed to be involved in the re-absorption 
of magnesium in the distal convoluted tubule and its 
extrusion into the capillaries are shown in Fig.  4. We 
believe, our patient loses magnesium via the distal 
convoluted tubule.
Oral magnesium replacement
Our patient was not well controlled on magnesium 
glycerophosphate while she had significantly better 
control on magnesium aspartate. In a study using rats, 
magnesium was better absorbed from organic magnesium 
salt replacements (magnesium aspartate and particularly 
magnesium gluconate) than from inorganic salt 
replacements (e.g. magnesium sulphate and magnesium 
carbonate) (17). That some magnesium salts are better 
absorbed than others is reflected in our patient in respect 
of higher serum magnesium levels upon switching 
replacement regime from magnesium glycerophosphate to 
magnesium aspartate. The estimated average requirement 
for magnesium for a 19- to 30-year-old female is 255 mg 
(10.6 mmol)/day. This increases to 290 mg (12.7 mmol)/
day in pregnancy and 255 mg (11.3 mmol/day) in 
lactation (18). Our patient may therefore benefit from a 
small amount of additional magnesium therapy during 
these periods if she achieves conception.
MODY5
Although not seen in our patient, HNF1B mutations can 
also cause maturity onset diabetes of the young type 5 
(MODY5). This is again thought to be mediated by the 
formation of cysts – this time in the pancreas, where 
mouse models have shown a reduction in expression 
of transcription factors downstream of Hnf1b, which 
are involved in the formation of pancreatic ducts and 
the development of endocrine cells. A reduction in the 
number of multipotent progenitor cells has also been 
noted, which resulted in pancreatic hypoplasia (19). In 
one study, it was noted that MODY5 generally occurred 
before the age of 30 years (20); therefore, our patient’s 
chances of developing diabetes mellitus are now probably 
lower. We will follow her glycaemic state with annual 
HbA1c and fasting glucose levels.
Uterine anomalies and reproductive considerations
LHX1, also located in the deleted area, is a transcription 
factor, which is essential for the normal development 
and elongation of the female reproductive tract (21). 
Interestingly, HNF1B can activate LHX1 (22). Patients 
with HNF1B point mutations, therefore without 
17q12 deletion and normal LHX1, can show genital 
abnormalities (23). In our patient, both mechanisms – 
loss of LHX1 or loss of HNF1B-induced stimulation of the 
LHX1 promoter – could play a role in the development 
of the uterine abnormality. Bicornuate uterus is one of 
the most common uterine malformations (24), and it is 
associated with a spontaneous abortion rate of 36%, a 
pre-term birth-rate of 23% and a live birth-rate of 55.2% 
(24, 25).
In summary, the heterozygous large deletion of 17q12 
area explains the complex phenotype of this patient.
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Figure 4
Mechanism of magnesium reabsorption into DCT cells and proposed 
mechanism for extrusion into the capillaries. Green channel, 
co-transporter; red channel, ion channel; orange channel, sodium 
potassium ATPase pump and purple channel, proposed mechanism for 
magnesium extrusion. EGFR, epidermal growth factor receptor.
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